Moderna rises after UBS lifs PT on upcoming pipeline updates

Moderna

04/05/2026 18:32

** Shares of vaccine maker Moderna MRNA.O rise 4.6% to $47.45

** UBS raises its PT on MRNA shares to $45 from $36, and maintains a "neutral" rating

** Brokerage says upcoming pipeline updates in 2026 could help improve investor sentiment around MRNA

** Says late-stage data from MRNA's personalized cancer vaccine for melanoma is its most important 2026 catalyst; adds it expects an interim readout from the melanoma study in late summer or early fall

** UBS also flags an FDA decision on MRNA's standalone flu vaccine, due in August, saying approval could help reduce risk around MRNA's flu-COVID combination shot

** Also points to a possible 2026 norovirus vaccine readout, saying the program has a 50/50 chance of success and could add $1 billion-$2 billion in sales if launched

** Including session's move, MRNA up 61.3% YTD

(Reporting by Kunal Das in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))